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Amyloid-betaMicroglial cells in the brains of Alzheimer's patients are known to be recruited to amyloid-beta (Aβ) plaques
where they exhibit an activated phenotype, but are defective for plaque removal by phagocytosis. In this
study, we show that microglia stressed by exposure to sodium arsenite or Aβ(1–42) peptides or ﬁbrils form ex-
tensive stress granules (SGs) towhich the tyrosine kinase, SYK, is recruited. SYK enhances the formation of SGs, is
active within the resulting SGs and stimulates the production of reactive oxygen and nitrogen species that are
toxic to neuronal cells. This sequestration of SYK inhibits the ability of microglial cells to phagocytose
Escherichia coli or Aβ ﬁbrils. We ﬁnd that aged microglial cells are more susceptible to the formation of SGs;
and SGs containing SYK and phosphotyrosine are prevalent in the brains of patients with severe Alzheimer's dis-
ease. Phagocytic activity can be restored to stressed microglial cells by treatment with IgG, suggesting a mecha-
nism to explain the therapeutic efﬁcacy of intravenous IgG. These studies describe a mechanism bywhich stress,
including exposure to Aβ, compromises the function of microglial cells in Alzheimer's disease and suggest ap-
proaches to restore activity to dysfunctional microglial cells.
© 2015 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Microglial cells (MG) are the professional macrophages of the cen-
tral nervous system. Among their many tasks is the removal from the
brain of aggregates of amyloid-beta (Aβ), which is formed from a pro-
teolytic product of amyloid precursor protein (Huang and Mucke,
2012). The persistent accumulation of Aβ plaques is a characteristic of
Alzheimer's disease (AD), a serious neurodegenerative disorder affect-
ingmillions of patientsworldwide.MGare attracted to sites of Aβ depo-
sition, which they recognize through a variety of cell surface receptors,
and are capable of Aβ removal through phagocytosis (Solito and
Sastre, 2012; Gandy and Heppner, 2013). Impaired microglial activity,
as exhibited by defective removal of Aβ plaques, is particularly associat-
ed with the later stages of AD as plaques accumulate (Krabbe et al.,
2013; Hickman et al., 2008; Mosher and Wyss-Coray, 2014). These
plaques still attract MG, but are refractory to phagocytosis. While
MG can phagocytose Aβ ﬁbrils, they also become activated as a conse-
quence of receptor engagement by Aβ (Meyer-Luehmann et al., 2008;sease; IgG, immunoglobulin G;
nal Chemistry and Molecular
g, 201 S. University St., West
. This is an open access article underJekabsone et al., 2006; Bianca et al., 1999). The activation of MG is
problematic as the resulting inﬂammatory response can damage neigh-
boring neuronal cells (Bianca et al., 1999). Compelling evidence for an
important role of MG in AD comes, in part, from large scale studies of
genes associated with AD that directly implicate inﬂammatory
responses of MG as critical for AD pathology. Products of genes with
identiﬁed associations with AD include TREM2, TYROBP and CD33
(Guerreiro et al., 2013; Jonsson et al., 2013; Bertram et al., 2008;
Hollingworth et al., 2011; Naj et al., 2011; Zhang et al., 2013). The mye-
loid receptor TREM2 functionally associates with TYROBP and promotes
the internalization of bacteria and apoptotic neurons and recruits MG to
Aβ plaques (N'Diaye et al., 2009; Takahashi et al., 2005, Wang et al.,
2015; Jay et al., 2015). Loss-of-function mutants promote inﬂammatory
responses, decrease phagocytosis and predispose patients to AD
(Guerreiro et al., 2013). CD33 is upregulated inMG inADbrain and is as-
sociatedwith reduced uptake of Aβ and increased numbers of activated,
pro-inﬂammatory MG (Griciuc et al., 2013).
Many phagocytic receptors contain or are associated with proteins
such as TYROBP that contain immunoreceptor tyrosine-based activation
motifs (ITAMs) (Linnartz et al., 2010; Cambier, 1995). Receptor engage-
ment initiates the phosphorylation of the two ITAM tyrosines leading to
a physical interaction with the tyrosine kinase, SYK (Geahlen, 2009).
Signaling through ITAM receptors is attenuated by receptors with
immunoreceptor tyrosine-based inhibitory motifs (ITIMs) such as
CD33 (Angata et al., 2002). Since SYK is essential for both phagocytosis
in macrophages and for the receptor-mediated activation ofthe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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events that are disrupted in MG from AD brains, it would appear to be
a prime candidate for a critical mediator of AD pathology. An important
question is how the function of SYK might be disrupted in aged or
stressed MG.
MG in aged and AD brain fail to clear Aβ plaques, but display an ac-
tivated, pro-inﬂammatory phenotype (Krabbe et al., 2013; Hickman
et al., 2008; Mosher and Wyss-Coray, 2014). How aging and other
stresses affect MG to alter their homeostatic functions is unclear. Eu-
karyotic cells respond to external stresses via the formation of ribonu-
cleoprotein (RNP) complexes scaffolded by RNA-binding proteins that
self-associate. Examples of RNP aggregates include stress granules
(SGs), which contain stalled initiation complexes and their associated
mRNAs (Anderson and Kedersha, 2008; Buchan and Parker, 2009). An
association of RNP aggregates with neurodegenerative diseases is well
documented and mutations in RNA-binding proteins that promote
self-assembly can be drivers of motor neuron diseases (Ash et al.,
2014; King et al., 2012). Similarly, defective clearance of SGs leads to
the pathological accumulation of RNP particles and underlies the
pathology of amyotrophic lateral sclerosis, Huntington's disease,
frontotemporal lobar degeneration and AD (Harris and Rubinsztein,
2011; Buchan et al., 2013; Koppers et al., 2012; King et al., 2012;
Vanderweyde et al., 2012; Waelter et al., 2001; Goggin et al., 2008;
Liu-Yesucevitz et al., 2010; Neumann et al., 2006; Menzies et al., 2015).
Large scale proteomic screens from our laboratory have identiﬁed
multiple SG-associated proteins as binding partners and substrates for
SYK (Iliuk et al., 2010; Xue et al., 2012; Galan et al., 2011). We found
that SYKwas recruited to SGs inMCF7 cellswhen exposed to sodium ar-
senite or proteasome inhibitors (Krisenko et al., 2015). In this study,
we show that SYK also is recruited to SGs that form in MG, not only in
response to sodium arsenite, but also in response to Aβ peptides or ﬁ-
brils. Chronic stress leads to the formation of persistent SGs in MG in
which active SYK is sequestered, leading to the constitutive production
of reactive metabolites and the inhibition of phagocytic activity. Cyto-
plasmic aggregates containing SYK and phosphotyrosine are more pro-
nounced inMG in thebrains of patientswith advancedAD. Based on this
information, we propose a model in which the production of SGs and
the corresponding misregulation of SYK directly contribute to AD pa-
thology. Interestingly, the impaired phagocytic activity of stressed MG
can be restored by the induced relocation of SYK from the SG to the plas-
ma membrane by treating cells with IgG, suggesting a mechanism by
which the administration of immunoglobulins to AD patients might re-
tard disease progression.
2. Material and Methods
2.1. Cells and Cell Lines
BV-2 microglial cells developed by Blasi and colleagues (Blasi et al.,
1990)were obtained fromDr. Chris Rochet (PurdueUniversity) and cul-
tured in DMEM media containing 10% FBS and 100 U/ml penicillin and
streptomycin. N9 microglial cells (Righi et al., 1989) were obtained
from Dr. Fabio Bianco (Neuro-Zone, Italy) and were cultured in
ISCOVE medium containing 10% FBS and 100 U/ml penicillin and strep-
tomycin. HEK293T cells were purchased from ATCC and HT22 neuronal
cells (Davis and Maher, 1994) were obtained from Dr. Shaohua Yang,
(University of North Texas). Both were grown in DMEM containing
10% FBS and 100 U/ml penicillin and streptomycin. The cDNA coding
for mouse SYK-EGFP fusion protein cloned into a puromycin resistance
lentiviral vector was as described (Wang et al., 2014). GIPZ mouse SYK
shRNA and scrambled shRNA lentiviral plasmids were purchased from
GE Dharmacon. Lentiviruses were packaged in HEK293T cells and
used to infect BV-2 cells, which were then selected in puromycin.
Primary microglial cells were isolated essentially as described
(Moussaud and Draheim, 2010; Lee and Tansey, 2013) from 1 month or
20 month old wild-type or Syk+/− C57BL/6 mice. SYK-haploinsufﬁcientmice were generated by gene targeting by Ingenious Targeting Labora-
tory, Ronkonkoma, NY. The endogenous gene for Syk was replaced by
a gene containing a GCA to AGC and AT to GC substitutions at nucleo-
tides 61,527–9 and 61,568–9, respectively, and a neomycin resistance
cassette 328 nucleotides upstream of exon 10. The resulting allele is
not expressed resulting in a loss of SYK from homozygous animals and
haploinsufﬁciency in heterozyotes (Supplemental Fig. 2A). Homozygous
knock-out animals are not viable and die shortly after birth. Brieﬂy, 5
mice from each groupwere anesthetized and perfused in the left ventri-
cle at constant pressure for 5minwith ice cold Ringer's solution contain-
ing 2 U/ml heparin. Brains were removed and meninges separated. The
brain was minced and dissociated in media containing 1 mg/ml papain,
1.2 U/ml dispase II and 20 U/ml DNase1. Cells were recovered, pipetted
up and down using glass Pasteur pipettes of decreasing hole sizes, ﬁl-
tered through 70 μm and 40 μm cell strainers and collected in media.
Cells were separated on a discontinuous percoll density gradient, col-
lected, washed, and cultured on 1% ﬁbronectin-coated dishes. Primary
microglia were conﬁrmed by Western blotting and immunoﬂuores-
cence staining of IBA1 (Moussaud andDraheim, 2010). Allmouse exper-
iments were performed according to the guidelines of IACUC at Purdue
University.
2.2. Stress Granule Formation
Cells were grown on poly-D-lysine coated cover slips in media con-
taining 1% FBS for 12 h before treatment with sodium arsenite (SA)
(1 μM), Aβ(1–42) (100 nM), or Aβ(1–42) ﬁbrils (100 nM) for the indi-
cated times. Aβ(1–42) (rPeptide) or Aβ(42–1) (American Peptide
Company) were resuspended in DMSO, 1% NH4OH at a concentration
of 0.025 M. To prepare Aβ ﬁbrils, DMSO soluble Aβ was sonicated for
30min at 1min intervals, shaken at 37 °C for 48h and then at room tem-
perature for 72 h (Dahlgren et al., 2002; Pan et al., 2011). Treated cells
were ﬁxed in 4% formaldehyde in PBS, permeabilized in 1% Triton
X-100, blocked with 5% goat or donkey serum (depending on the spe-
cies of origin of the secondary antibody) and incubated overnight at
4 °Cwithprimary antibody diluted at a ratio of 1:1000 in 5% goat or don-
key serum in PBS. Secondary antibodies Alexa Fluor 488 or 594 against
mouse, rabbit, goat and donkey species were purchased from Life Tech-
nologies. Nuclei were visualized by staining with Hoeshct 33,342
(Sigma-Aldrich). Coverslips were mounted with ProLong® Gold
Antifade reagent (Life Technologies) and examined using a Zeiss LSM
710 confocal microscope. Five 25× frames (average of 75 cells each
frame) were randomly selected from three independent experiments
and regions surrounding SGswere selected and corrected total cell ﬂuo-
rescence (CTCF)was calculated using ImageJ. CTCFwas used tomeasure
the SG area in arbitrary units also known as brightness values. The
number of SGs was manually calculated from ﬁve random 63× frames
(average of 25 cells each frame) from three independent experiments
using Zeiss 2012 software. All statistical calculations were done using
GraphPad Prism 6 and one-way ANOVA statistical test was performed
to calculate the P-value. SG formation in primary cells was analyzed
by two-way ANOVA. Error bars in the ﬁgures represent means ± SEM.
2.3. Western Blotting and Immunoprecipitation Assays
For general immunoblotting experiments, N9, BV-2 or primary
microglial cells were lysed in buffer containing 1% NP-40, 50 mM
Tris/HCl, pH 8.0, 150 mM NaCl, 5× protease inhibitor cocktail (13,911,
Sigma-Aldrich), 10 μM sodium orthovandate for 15 min on ice. After
centrifugation at 14,000 ×g for 10 min, supernatants were collected,
separated by SDS-PAGE and analyzed by Western blotting. To prepare
soluble and insoluble fractions, cells were lysed in buffer A (15 mM
Tris–HCl, pH 7.6, 0.3 M NaCl, 15 mM MgCl2, 1% Triton X-100, 10 mM
Ribonucleoside Vanadyl Complex (New England Biolabs), 5× protease
inhibitor cocktail and 10 μM sodium orthovanadate) on ice for 10 min.
Cells were disrupted by mortar and pestle. The insoluble fraction was
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collected as the soluble fraction. The insoluble fraction was dissolved in
SDS-sample buffer.
For immunoprecipitation assays, whole cell lysates prepared in buff-
er Awere incubatedwith anti-phosphotyrosine (4G10, EMDMillipore)-
coated protein Gmagnetic beads (Sigma-Aldrich) for 2 h at 4 °C or with
GFP-Trap beads (ChromoTek) for 30 min. Beads were washed
thoroughly and boundproteins elutedwith SDS-sample buffer. Immune
complexes were examined by Western blotting to identify associated
proteins.
2.4. Microglial Cell Functional Assays
Phagocytic activity of N9 and BV-2 cells was assessed by the uptake
of pHrodo™ Red E. coli BioParticles® (Life Technologies) or ﬂuorescein
labeled Aβ(1–42) ﬁbrils (rPeptide). N9 and BV-2 cells were grown in
poly-D-lysine coated glass bottom dishes (MatTek) for 12 h in growth
media containing 1% FBS and then treated as indicated for 120 h. Cells
were incubated in 2 ml Live Cell Imaging Solution (Life Technologies)
with 100 μl pHrodo™ particles for 1 h in 5% CO2 and 37 °C on a confocal
microscope stage. Hoechst dye was added to visualize the nucleus. Live
images of cells were taken at 30 s intervals and compiled into a video.
For ﬁxed cell images, cells incubated for 1 h were ﬁxed and examined
by confocal microscopy. Phagocytosis of ﬂuorescent red particles was
quantiﬁed by measuring the mean corrected ﬂuorescence intensity
using ImageJ software from ﬁve random equal sized frames for each
treatment condition. The phagocytosis of Aβ ﬁbrils was measured
using N9 cells in a similar manner except cells were incubated for 1 h
with 25 μl FITC-labeled Aβ ﬁbrils (ﬁbrils prepared from 0.25 M solution
of soluble Aβ(1–42)). Cells were washed extensively, ﬁxed and imaged
by confocal microscopy.
Intracellular ROS production was measured using both the
5(6)-carboxy-2′,7′-dichlorodihydroﬂuorescein diacetate (carboxy-
H2DCFDA) (Setareh Biotech) and dihydrorhodamine 123 (D123) (Life
Technologies) reagents. N9 cells were grown in 96-well plates in
media containing 1% FBS and treated as indicated with SA or Aβ in
the presence or absence of 500 nM SYK kinase inhibitor (R406 or
PRT-060318 (Selleckchem)) for 120 h. Carboxy-H2DCFDA (10 μM)
was added and incubated at 37 °C for 1 h. Cells were washed 3 times
with PBS. Fluorescence was measured using a microplate reader. Alter-
natively, treated and control cells were incubated with D123 (5 μM) for
1 h. Cells were stained with Hoechst dye, ﬁxed and examined by confo-
cal microscopy. Quantitative analyses used Image J to measure mean
ﬂuorescence intensity. Extracellular production of H2O2 was measured
using Acridan Lumigen PS-3 reagents (Amersham) as described
(Uy et al., 2011). Chemiluminescence was detected using a lumines-
cence plate reader at 430 nm. N9 cells grown in media containing
1% FBS were plated on 1% ﬁbronectin-coated 24 well plates and treated
with SA, Aβ and/or SYK inhibitors for 120 h.Mediawas collected and re-
active nitrogen species quantiﬁed by measuring nitrite levels using the
Measure-iT™ High-Sensitivity Nitrite Assay Kit (Life technologies) ac-
cording to manufacturer's instructions. Fluorescence was measured
using a microplate reader (excitation/emission 365/450 nm).
Cytokine production wasmeasured using themouse ER stress ELISA
strip (Signosis) according to manufacturer's instructions.
2.5. Microglia-Neuron Co-culture and Annexin V Assay
N9 microglial cells (5 × 103 cells/well) plated in poly-D-lysine-coat-
ed 24-well plates were treated as indicated with SA, Aβ and/or SYK in-
hibitor for 120 h. Cells were gently detached and washed with PBS.
5 × 102 cells from each treatment condition were added to an 8 μm
pore size transwell insert and placed atop 1.5 × 104 HT22 cells plated
in DMEM media without phenol red containing 1% FBS and 100 U/ml
penicillin and streptomycin and incubated for 48 h. HT22 cells werestained with FITC Annexin V (BD Biosciences) and Hoechst dye, ﬁxed
and examined by confocal microscopy.
2.6. Human AD Clinical Samples
Parafﬁn-ﬁxed human AD brain and normal brain cortex samples
were obtained from the Brain and Body Donation Program, Banner
Sun. Health Research Institute, Arizona (Beach et al., 2015). Samples
were clinically evaluated based on several criteria including mini-
mental state examination (MMSE) score, plague density, Lewy body
prevalence and dementia. Parafﬁn ﬁxed cortex brain slices were heated
at 65 °C for 30 min, ﬁxed with 4% paraformaldehyde, washed sequen-
tially with different concentrations of ethanol (70%, 50%, 30%) and
then subjected to antigen retrieval by heating in 10 mM Tris/HCl
(pH 10) for 20 min at 85 °C. Slides were blocked with 5% donkey
serum and 2% BSA overnight at 4 °C. Brain slices were stained using an-
tibodies against SYK, IBA1, G3BP and phosphotyrosine and examined
using a Zeiss 710 LSM confocal microscope.
2.7. Antibodies
The antibodies and sources used in this study were as follows: SYK
(D3Z1E, Cell Signaling Technology or B01P, Abnova), phospho-SYK
(Tyr525/526, 2711, Cell Signaling Technology), G3BP1 (611,126, BD
Biosciences or 07–1801, EMD Millipore), pEIF2α (E90, Abcam),
TIA-1(ab2712, Abcam), PABP1 (ab21060, Abcam), GFP (168AT1211,
Abgent), GAPDH (6C5, Ambion), pTYR (4G10, EMD Millipore), IBA1
(ab5076, Abcam), GFAP (GF5, Abcam), TDP-43 (10,782–2-AP,
Proteintech), NOS2 (ab3523, Abcam), Integrin β1 (4B7R, Santa Cruz
Biotech), CD32 (ab197930, Abcam), and Rabbit IgG (Sigma-Aldrich).
3. Results
3.1. SYK Localizes to Stress Granules in Microglial Cells
Due to the small size of primarymicroglial cells, whichmakes imag-
ing challenging, we ﬁrst established the parameters for investigations at
the cellular level using two established lines of cultured MG: BV-2 and
N9. Immunoblotting for endogenous SYK revealed a high level of ex-
pression of SYK in both cells as shown in comparison to DG75 B cells
(Fig. 1A). To determine if SGs form in these MG, we treated each with
sodium arsenite (SA), themost commonly used inducer of SGs. Numer-
ous SGs were found in both cell lines when treated with low concentra-
tions of SA (1 μM) for 24 h as revealed by the appearance of puncta that
stained with the SG marker G3BP1 (Fig. 1B). To determine if SYK local-
ized to these SGs, we ﬁxed and stained cells with an antibody against
the kinase. A fraction of SYK co-localized with G3BP1 in SGs in both
cell types when treated with SA (Fig. 1B). The concentration of SA that
was required to induce SGs was surprisingly low compared to the
level commonly used to induce SGs in other cell types (McEwen et al.,
2005). We then asked if exposure to a stressor known to be involved
in neurodegeneration would lead to SG formation. When treated with
100nMsoluble Aβ(1–42) for 24 h, abundant SYK-positive SGs appeared
in both BV-2 and N9 cells (Fig. 1C). Quantitative analyses revealed a
ﬁve-fold increase in area containing co-localized SYK andG3BP1 follow-
ing treatment with SA or Aβ (Fig. 1D). Cells did not form SGs when
treated with Aβ(42–1) (Fig. 1E).
We then asked if other proteins commonly found in SGs were pres-
ent within these complexes in MG. N9 cells were treated with SA or Aβ
for 24 h, ﬁxed and stained for SYK and co-stained for phosphorylated
EIF2α, PABP1, TDP-43 and TIA-1. SYK-positive puncta produced by
both stimuli contained each of these proteins (Fig. 2A). Similar results
were seen in BV-2 cells (Supplemental Fig. 1A). G3BP1 also co-
localized in puncta with pEIF2α, TDP-43 and TIA-1 in N9 cells treated
with SA or Aβ (Fig. 2B). Since SGs are insoluble in mild detergents,
we fractionated control and stressed MG into detergent-soluble and
Fig. 1. SYK associates with SGs in MG. (A) Lysates of BV-2, N9 and DG75 cells were examined byWestern blotting using antibodies against SYK and GAPDH. (B) BV-2 and N9 cells were
treatedwithout (control) or with SA (A) for 24 h, ﬁxed and stained for SYK (green) and G3BP1 (red). Examples of SGs are indicated by the arrows. Bar= 10 μm. (C) The area occupied by
SYK and G3BP1 positive SGs inN9 cells was quantiﬁed by Image J analysis of 5 random frames from3 independent experiments. Results representmeans± SEM. *P=0.001. (D) BV-2 and
N9 cells were treatedwithout (control) orwith soluble Aβ for 24 h,ﬁxed and stained for SYK (green) andG3BP1 (red). Examples of SGs are indicated by the arrows. Bar=10 μm. (E) BV-2
cells were treated with soluble Aβ(42–1) for 24 h, ﬁxed and stained for SYK (green) and G3BP1 (red). Only merged images are shown.
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and TIA-1. A signiﬁcant increase in the presence of SYK, G3BP1,
pEIF2α and TIA-1 in the detergent-insoluble fractions accompanied
treatment of both N9 cells with either SA or Aβ (Fig. 2C). Similar results
were seenwith BV-2 cells (Supplemental Fig. 1B). To further conﬁrm an
interaction of SYK with SG markers, we expressed SYK-EGFP in BV-2
cells, which were then treated with SA or Aβ, and immunoprecipitated
the tagged protein from the SG enriched fraction. Both stress stimuli re-
sulted in an increased association of SYK-EGFP with endogenous SYK,
G3BP1 and pEIF2α (Supplemental Fig. 1C).
3.2. SYK is Recruited to SGs in Primary MG
To conﬁrm that SYK also was recruited to SGs in primary cells, we
isolated MG from brains of mice either 1 month or 20 months of age.
Isolated cells were positive for the MGmarker IBA-1, but lacked the as-
trocyte marker GFAP (Supplemental Fig. 2B & C). When primary MG
were treated with SA or Aβ for 24 h, ﬁxed and stained for IBA-1, SYK
and G3BP1, we found SYK- and G3BP1-positive puncta formed in
response to both stress stimuli. Interestingly, SGs were especially abun-
dant in cells isolated from aged (20 months) animals (Fig. 3A andSupplementary Fig. 2D), indicating that cells from older animals are
particularly sensitive to external stress stimuli.
To determine if SYK itself might play a role in the stress-induced for-
mation of SGs, we further compared MG from wild type mice to cells
isolated from SYK haploinsufﬁcient mice. MG isolated from the brains
of haploinsufﬁcient mice expressed half as much SYK as did cells from
wild-type animals (Supplemental Fig. 2B). SG formation was compara-
ble in cells from one month old Syk+/+ and Syk+/− animals (Supple-
mental Fig. 2D & E), but was reduced considerably in cells isolated
from the brains of 20 month old Syk+/−mice (Fig. 3B) as compared to
their wild-type counterparts (Fig. 3A & C). Since a complete SYK knock-
out was lethal as seen previously (Turner et al., 1995), we were unable
to test cells from Syk−/− animals. These results suggested that SYK may
actually promote the formation of SGs in MG.
3.3. SYK Promotes SG Formation
The reduced appearance of SGs in cells from agedmicewith reduced
levels of SYK as compared to agedmicewith normal levels of the kinase
suggested a possible role for the kinase in SG induction. To determine if
SYK was active when recruited to SGs, we stained control and SA- and
Fig. 2. Characterization of SGs inMG. (A and B) N9 cells were treatedwithout (control) or
with SA or soluble Aβ for 24 h, ﬁxed and stained for SYK, pEIF2α, PABP1, TDP-43, TIA-1
and/or G3BP1 as indicated. Only merged images are displayed. Examples of SGs are indi-
cated by the arrows. Bar = 10 μm. (C) N9 cells were treated without (−) or with (+)
SAor soluble Aβ for 24 h and then separated into detergent soluble and insoluble fractions,
which were analyzed by Western blotting for SYK, G3BP1, TIA-1 and pEIF2α. Data shown
are representative of three separate experiments.
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SYK-positive puncta induced by either stimulus contained abundant
phosphotyrosine indicating that SYKwas active in SGs (Fig. 4A). Similar
results were observed in BV-2 cells (Supplemental Fig. 3A). Quantiﬁca-
tion of images conﬁrmed a signiﬁcant increase in area containing co-
localized SYK and phosphotyrosine (Supplemental Fig. 3B). To conﬁrmthe presence of active SYK in SGs, we immunoprecipitated tyrosine-
phosphorylated proteins from control, SA- and Aβ-treated N9 cells
and immunoblotted the immune complexes for phosphotyrosine and
SYK. Induction of SGs with either stimulus resulted in a signiﬁcant in-
crease in the phosphorylation of multiple proteins including SYK itself
(Fig. 4B). Western blotting of lysates of control and SA- or Aβ-treated
N9 cells with antibodies speciﬁc for the phosphorylated activation
loop of SYK conﬁrmed that SYK was active and phosphorylated in
response to both stimuli (Fig. 4C).
To determine if active SYK plays a role in SG formation, we stimulat-
ed BV-2 cells with SA or Aβ for 24 h in the absence or presence of a SYK
inhibitor. We used two distinct inhibitors, R406 and PRT318, to avoid
potential complications of off-target effects. In the presence of either
inhibitor, neither SA nor Aβ induced the formation of signiﬁcant SGs
(Fig. 4D & E). The ability of each inhibitor to reduce SYK activity
was conﬁrmed by the Western blotting with anti-SYK and
antiphosphotyrosine antibodies of lysates of BV-2 cells treated with
H2O2 in the presence or absence of R406 or PRT318. H2O2, an inhibitor
of tyrosine phosphatases, led to the activation of SYK and its autophos-
phorylation on Y317with a resulting shift in its electrophoreticmobility
(Keshvara et al., 1998), which was lost in inhibitor-treated cells
(Supplemental Fig. 3C).
To further conﬁrm a direct role for SYK in SG formation, we infected
BV-2 cells with lentiviruses expressing EGFP and either shRNA against
SYK or a scrambled shRNA. SYK levels were selectively reduced in cells
expressing the SYK shRNA while levels of G3BP1 were unaffected
(Fig. 5A). Infected cells were treated with SA or Aβ for 24 h, ﬁxed and
stained for G3BP1. While cells infected with scrambled shRNA readily
formed SGs, cells with reduced levels of SYK failed to do so (Fig. 5B
and D). As expected, the appearance of SYK in SGs was reduced in the
knockdown cells (Fig. 5C).
3.4. Chronic Stress Induces Large and Persistent SGs
SGs formed in cells exposed to SA or Aβ for 24 hwere largely cleared
within 24 h after removal of the stress stimulus (Supplemental Fig. 4A).
However, it has been proposed that exposure to chronic stress leads to
the formation of persistent SGs in the brain (Ash et al., 2014). To
model this in MG in vitro, we exposed N9 cells to low levels of SA or
Aβ for a period of ﬁve days to mimic chronic stress. Prolonged stress
led to the formation of very large SGs that contained both SYK and
G3BP1 (Fig. 6A). To examine the clearance of these SGs, we removed
the stress and allowed cells to recover for 48 h. While the intensity of
staining for G3BP1declined somewhat, the areawithin the cell occupied
by SGs was largely unchanged (Fig. 6A and Supplemental Fig. 4B).
3.5. Chronic Stress Induction Leads to SYK-dependent Generation of ROS
and RNS
We next explored the possible consequences of the presence of acti-
vated SYK in SGs in chronically stressedMG. The receptor-mediated ac-
tivation of SYK in macrophages and microglial cells is coupled to the
production of both ROS and RNS (McDonald et al., 1997; Yi et al.,
2014) and the generation of both reactive oxygen and nitrogen species
(ROS and RNS) by MG can be damaging to neighboring neuronal cells
(Cameron and Landreth, 2010). To determine if chronic stress led to
constitutive ROS generation, we treated N9 cells with SA or Aβ for
5 days and then measured the relative amounts of ROS produced over
the course of 1 h by monitoring the oxidation of cell permeant DCFDA.
Cells chronically stressed by exposure to either SA or Aβ produced sub-
stantially more ROS than control cells (Fig. 6B). Similar results were
seen when we monitored the conversion of dihydrorhodamine 123 to
rhodamine 123 as a measure of ROS production (Fig. 6E). Consistent
with these results, cells chronically exposed to either SA or Aβ released
substantiallymore ROS into themedia than did untreated cells (Fig. 6C).
ROS production in cells treated with either stress stimulus was largely
Fig. 3. SYK associateswith SGs inMG from agedmice. (A and B)MG isolated from thebrains of 20month oldwild-type (A) or Syk+/− (B)micewere treatedwithout (control) orwith SA or
soluble Aβ for 24 h,ﬁxed and co-stained for IBA1 and SYK or IBA1 andG3BP1. Examples of SGs are indicated by the arrows. Bar=5 μm. (C)Quantitative comparison of SG formation inMG
from young (1 m) and old (20 m), wild-type (Wt) and Syk haploinsufﬁcient (Het) mice. **P= 0.001.
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C & E).
Next we examined changes in the release of RNS by measuring ni-
trite levels in the media. Nitrite release increased three-fold from N9
cells thatwere chronically stimulated by SA or Aβ (Fig. 6D). Again, levels
were reduced signiﬁcantly if cells were activated in the presence of a
SYK inhibitor. Since the formation of RNS in MG is mediated by NOS2
(Mosher and Wyss-Coray, 2014), we measured NOS2 levels in control,
SA- and Aβ-treated N9 cells by Western blot (Fig. 6G) andimmunoﬂuorescence (Supplemental Fig. 4E). An increase in the expres-
sion of NOS2 was observed following both stress stimuli. The induction
of NOS2 was reduced substantially in cells in which the activity of SYK
was inhibited.
Since ROS and RNS increased in chronically stressedMG, we asked if
this could contribute to neuronal cell death. To test this, we co-cultured
HT22 neuronal cells with N9 cells separated by a transwell insert. When
chronically SA- and Aβ-treated N9 cells were cultured with healthy
HT22 cells for two days, we observed a signiﬁcant increase in annexin
Fig. 4. SYK is active in SGs and promotes their formation. (A) N9 cells were treated without (control) or with SA or soluble Aβ for 24 h, ﬁxed and stained for SYK (green) and
phosphotyrosine (pTYR, red). Examples of SGs are indicated by the arrows. Bar=10 μm. (B) Phosphotyrosine-containing proteinswere immunoprecipitated from lysates of N9 cells treat-
edwithout (control) orwith SA or solubleAβ for 24 h. Immune complexeswere examined byWestern blottingwith antibodies against SYK or phosphotyrosine (pTYR). SYK in the original
lysates was detected by Western blotting (input). Beads lacking anti-phosphotyrosine were used as a control (mock). (C) Lysates from N9 cells treated without (control) or with SA or
solubleAβ for 24 hwere analyzedbyWestern blotting using antibodies against SYK phosphorylated onY519 and Y520 (p-SYK), SYK or GAPDH. (D)N9 cellswere treatedwithout (control)
or with SA or soluble Aβ for 24 h in the presence or absence of R406 or PRT318 (PRT) (500 nM each), ﬁxed and stained for SYK (green) and G3BP1 (red). Examples of SGs are indicated by
the arrows. Bar = 10 μm. (E) The number of SGs formed per cell from (D). Results represent means ± SEM from 3 independent experiments. *P= 0.0001.
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observed when HT22 cells were cultured with N9 cells that were
pretreated with SA or Aβ in the presence of PRT318. To conﬁrm an in-
crease in ROS and RNS in the co-culture media containing activated
N9 cells, wemeasured the levels of each generated over the two day in-
cubation period. A substantial increase in both ROS and RNS was ob-
served when SA- or Aβ-treated N9 cells were co-cultured with HT22cells (Supplemental Fig. 4C & D). The inhibition of SYK with either
PRT318 or R406 reduced the external ROS and RNS levels signiﬁcantly.
We also compared the media of cells chronically stressed by expo-
sure to Aβ for 120 h in the presence of absence of PRT318 for the secre-
tion of IFNγ, IGF-1, IL-1β, IL-6, leptin,MCP-1, TFGβ and TNFα, relative to
levels secreted by untreated cells. The levels of IFN-γ, MCP-1 and IL-1β
were signiﬁcantly increased in chronically stressed cells. Of these, both
Fig. 5. Reduced SYK inhibits SG formation in MG. (A) BV-2 cells expressing EGFP and scrambled shRNA or SYK shRNA were examined by Western blotting with antibodies against SYK,
G3BP1, GFP and GAPDH. (B and C) BV-2 cells infected with a lentivirus expressing EGFP and either a SYK or scrambled shRNA were treated without (control) or with SA or soluble Aβ
for 24 h, ﬁxed and stained for G3BP1 (B) or SYK (C) (both in red). Examples of SGs are indicated by the arrows. Bar = 10 μm. (D) Quantiﬁcation of G3BP1 positive SGs present within
10 random 25× frames for cells expressing SYK shRNA (SYK (−)) or scrambled shRNA (Scram). *P= 0.001.
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inhibitor PRT318 (Supplemental Fig. 5A).
3.6. SG Formation in Microglial Cells Impairs Phagocytosis
Despite their apparent activated phenotype, one important func-
tion of MG that is compromised in aged and AD brains isphagocytosis. Phagocytosis in myeloid cells through many receptors
is a SYK-dependent process, suggesting that the sequestration of SYK
in SGs away from membrane-associated phagocytic receptors might
compromise their function. To determine if chronic stress negatively
affects phagocytic activity, we treated BV-2 or N9 cells with SA or Aβ
for 5 days and then assayed the cells for the uptake of pH sensitive
E. coli BioParticles, which ﬂuoresce only following ingestion. Cells
Fig. 6. Chronic stress leads to large SGs and persistent ROS and RNS production. (A) N9 cells were treatedwithout (control) or with SA or soluble Aβ for 5 days.Where indicated, cells were
cultured in the absence of SAorAβ for an additional 48 h. Cellswereﬁxed and stained for SYK (green) andG3BP1 (red). Examples of SGs are indicated by the arrows. Bar=10 μm. (B-D)N9
cells were treated without (Control) or with SA or Aβ for 5 days in the presence or absence of R406 or PRT318 (500 nM each). Cells were incubated with carboxy-DCFDA (10 μM) for 1 h
and examined using a ﬂuorescence plate reader (B). Media was collected and analyzed for ROS using a chemiluminescence assay (C) or nitrite levels using a ﬂuorescence assay (D). Data
represent means± SEM for 3 independent experiments. *P=0.001, **P=0.0001. (E) N9 cells treatedwithout (control) or with SA or Aβ for 5 days in the presence or absence of PRT318
(500 nM) were incubated with D123 for 1 h and green ﬂuorescence was observed by confocal microscopy. Hoechst dye (blue) was used to stain the nucleus. Bar = 10 μm. (F) N9 cells
treated for 5 days with SA or Aβwere washed thoroughly and then co-cultured with HT22 for another 48 h separated by a transwell insert. HT22 cells were incubated with FITC Annexin
V (green) for 30min, ﬁxed and imaged by confocalmicroscopy. Hoechst dye (blue)was used to stain the nucleus. Bar=10 μm. (G) Lysates from the cells in (D)were analyzed byWestern
blotting for NOS2 and GAPDH.
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amined by live cell imaging as shown for N9 cells in Supplemental
Movies 1–3. For both cell types, chronic stress induced by either SA
or Aβ strongly impaired the uptake of the pHRhodo particles.Phagocytic activity was inhibited as well when cells were treated
with either R406 or PRT318 even in the absence of SA or Aβ
supporting an important role for SYK in phagocytosis (Fig. 7A & B).
Uptake of pHRhodo particles was blocked by the incubation of cells
Fig. 7. SYK inhibitors or chronic stress blockMG phagocytosis. (A) BV-2 cells were treated
without (control) orwith SA or soluble Aβ for 5 days in the presence or absence of R406 or
PRT381 (500 nMeach) and examined for the uptake of pHRodo particles (red). Cells were
ﬁxed and examined by confocal microscopy. Hoechst dye (blue)was used to stain the nu-
cleus. Bar = 10 μm. (B) Quantiﬁcation of (A) showing change in mean ﬂuorescence mea-
sured by Image J from ten random frames in three independent experiments. *P= 0.001
as compared to control cells, **P=0.0001 as compared to control cells. (C)N9 cells treated
without (control) orwith SA or soluble Aβ for 5 dayswere incubatedwith FITC-labeled Aβ
ﬁbrils for 12 h, washed, ﬁxed and examined by confocal microscopy. Hoechst dye (blue)
was used to stain the nucleus.
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particle uptake (Supplemental Fig. 5B).
An important function ofMG is to clearβ-amyloid plaques. To exam-
ine the effects of stress on this process, we treatedN9 cellswith SA or Aβ
for 5 days and measured their ability to take up ﬂuorescein-labeled Aβ
ﬁbrils. Again, control cells readily phagocytosed Aβ ﬁbrils whereas
chronically stressed cells were unable to do so (Fig. 7C & Supplemental
Fig. 5D). Similar to soluble Aβ, Aβ ﬁbrils also induced the formation of
SGs containing both SYK and G3BP1 when added to either BV-2 or N9
cells (Supplemental Fig. 5E).3.7. SYK Associated SGs are Formed in Brains of AD Patients
MG in patients with AD are chronically exposed to external sources
of stress including interactions with Aβ aggregates. Since prolonged
stress of MG in vitro resulted in the development of persistent SGs to
which SYK was recruited, we asked if a similar response might be asso-
ciated with AD. To explore this, we examined brain samples from pa-
tients with no, mild, moderate or severe AD (Supplemental Table 1).
Parafﬁn-ﬁxed sections of brain cortex were stained with antibodies
against IBA1, SYK, G3BP1 and/or phosphotyrosine. SYK was diffusely
distributed in MG in patients with no AD and in patients with mild dis-
ease, but was increasingly present in large puncta with escalating dis-
ease severity (Fig. 8A & Supplemental Table 1). SYK co-localized
within these puncta in diseased brain with both G3BP1 and
phosphotyrosine indicating that the kinase was localized to SGs and
was active at these sites (Fig. 8B & C).
3.8. Recovery of Impaired Phagocytosis by IgG
We then asked if manipulations of SYK activity or localization might
restore the ability of chronically stressed MG to phagocytose foreign
particles. Since integrin ligation leads to the activation of SYK in macro-
phages (Mócsai et al., 2006), we ﬁrst treated chronically stressed N9
cells with rabbit IgG directed against β1 integrin. Treatment of stressed
N9 cells for 4 h led to amarked recovery of phagocytic activity (Fig. 9A).
As a control, we treated stressed N9 cells with nonspeciﬁc rabbit IgG
isotype control antibodies. Interestingly, phagocytic activity was again
restored (Fig. 9A). To explore this further, we treated stressed cells
with an afﬁnity puriﬁed rabbit IgG directed against a peptide from the
cytoplasmic C-terminus of the inhibitory receptor CD32, an antibody
that should neither react with intact MG nor activate SYK. Again, incu-
bation with this antibody led to a recovery of phagocytic activity in
chronically stressed cells (Fig. 9A). Thus, phagocytic activity in stressed
MG could be restored by treatment with IgG independent of the speci-
ﬁcity of the antibody.
To explore a mechanism for the recovery of phagocytic activity, we
examined the effects of IgG on the localization of SYK in the cell. Treat-
ment of N9 cellswith either non-speciﬁc rabbit IgG or the anti-CD32 an-
tibody led to a relocalization of SYK from the cytoplasm to the plasma
membrane, the site where phagocytosis takes place. Even in chronically
stressed cells, a substantial amount of SYKwas translocated from SGs to
themembrane (Fig. 9B).Western blotting of detergent-soluble fractions
of N9 cells conﬁrmed the partial re-location of SYK to the detergent-
soluble fraction following incubation with rabbit IgG or anti-CD32
(Supplemental Fig. 6). These results indicate that it may be possible to
restore the phagocytic activity of chronically stressedMGbymanipulat-
ing the intracellular localization of SYK.
4. Discussion
Paradoxically, MG from aged and AD brain exhibit a phenotype that
combines a perpetually activated state with functionally impaired
phagocytic activity (Gandy and Heppner, 2013; Mosher and
Wyss-Coray, 2014). To explain this dichotomy, we propose a model in
which the altered activity and localization of SYK contributes to both
phenotypes. In this model, chronic stress leads to the formation of SGs
to which SYK is recruited resulting both in a pro-inﬂammatory pheno-
type and impaired phagocytosis. Impaired phagocytosis leads to further
accumulation of Aβ plaques that potentiate SG formation leading to
persistent inﬂammation and neuronal cell damage.
SG formation is thought to be, at least initially, a defense against
stress, providing a mechanism for the selective sequestration and pro-
tection from degradation of a subset of mRNAs (Anderson and
Kedersha, 2008). However, it is clear that persistent formation of RNP
particles is deleterious to cells as noted for several neurodegenerative
disorders where aggregates appear in neuronal cells (Harris and
Fig. 8. SYK, G3BP1 and phosphotyrosine-positive SGs are found in ADbrains. (A–C) Samples from the cortex region of human brain frompatients with no (normal), mild, moderate (mod)
and severe AD were immunostained for IBA1, SYK, G3BP1 and/or phosphotyrosine (pTYR) as indicated. Bar = 5 μm.
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form, as well, in MG. In fact, MG appear particularly susceptible to the
stress-induced formation of SGs as their induction requires exposure
only to low levels of SA or Aβ.
The recruitment of SYK to SGs in non-inﬂammatory cells protects
them from short-term, stress-induced damage by stimulating SG clear-
ance through autophagy, an event that requires both SYK activity and its
association with SGs (Krisenko et al., 2015). This process may be opera-
tive aswell inMG as SGs can be cleared effectively from cells exposed to
stress for short periods of time. However, prolonged stress leads to the
formation of large SGs that associate with SYK and are resistant toclearance as they persist following removal of the stimulus. We ﬁnd
that large SGs are characteristic of MG in the brains of patients with ad-
vanced AD, suggesting that these cells have been exposed to persistent
stress stimuli. This is consistent with observations that oxidative stress
often precedes the pathogenesis of AD since enhanced neuroinﬂamma-
tion resulting from traumatic brain injury or infection predispose individ-
uals to AD (Perry et al., 2002; Grifﬁn, 2013) while the long-term use of
NSAIDS can be protective (Vlad et al., 2008). The pronounced sensitivity
of primary MG from aged mice to SA- or Aβ-induced SGs suggests that
MG in the brains of elderly patients may be particularly prone to the
stress-induced formation of SGs consistent with advanced age as the
Fig. 9. Restoration of phagocytic activity with IgG. (A and B) N9 cells were treatedwithout
(control) or with SA or soluble Aβ for 120 h in the presence or absence of R406 or
PRT318 (500 nM each). At 116 h, to one set of control, SA- and Aβ-treated cells was
added anti-β1-integrin (β-Int), mixed rabbit IgG (IgG) or anti-CD32 for the ﬁnal 4 h.
Cells were then incubated with pHRhodo particles (red) to measure phagocytosis (A) or
ﬁxed and stained with antibodies against SYK (B). Hoechst dye (blue) was used to stain
the nucleus (A). Bar = 10 μm.
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of SYK- and phosphotyrosine-containing puncta in brain samples may
serve as a usefulmarker of stressed anddysfunctionalMG inneurodegen-
erative disease.The formation of SGs in MG in response to low levels of either SA or
Aβ requires the activity and expression of SYK as it is blocked by SYK in-
hibitors or by a knockdown or reduction of SYK expression. In inﬂam-
matory cells like MG, SYK plays a well known role in the receptor-
mediated production of ROS and RNS (Yi et al., 2014). Aβ binds to MG
via an assortment of cell surface receptors (Mosher and Wyss-Coray,
2014) many of which, including CD14, TLR4, CD36, and SIRPβ1, are
coupled to SYK either directly or through receptor-associated proteins
that contain ITAMs (Miller et al., 2012; Heit et al., 2013; Gaikwad
et al., 2009; Dietrich et al., 2000; Bamberger et al., 2003). The interac-
tions ofmicroglial cellswith Aβ leads to the phosphorylation and activa-
tion of LYN and SYK, which are coupled to the generation of superoxide
radicals and lead to neurotoxicity (McDonald et al., 1997; Combs et al.,
1999; Sondag et al., 2009). SYK also is activated in cells under conditions
of increased oxidative stress (Schieven et al., 1993). The resulting
SYK-dependent pro-inﬂammatory response may be further exacerbat-
ed by the retention within SGs of active SYK—as reﬂected by the pres-
ence of phosphotyrosine-containing proteins—which may continue to
stimulate downstream signaling pathways that generate ROS or RNS.
The production of ROS and RNS can be damaging to neighboring cells
(Mosher andWyss-Coray, 2014) andweﬁnd, in fact, that chronically ac-
tivated MG produce mediators that are toxic to HT22 neuronal cells.
Consistent with a role for SYK in these processes, the generation of
chronically activated MG that produce ROS and RNS and the ability of
these cells to kill neuronal cells are all blocked by SYK inhibitors. Inter-
estingly, chronically stressed MG also produce increased quantiﬁes of
IFNγ and MCP-1/CCL2, cytokines reported previously to be produced
by MG in response to stress associated with Parkinson's disease or
inﬂammation (Barcia et al., 2012; D'Mello et al., 2009).
The ability ofMG to clear Aβ plaques through phagocytosis is impor-
tant for the control of AD (Bamberger et al., 2003; El Khoury et al., 2007).
Chronic stress induced by prolonged exposure of MG to either SA or Aβ
inhibits the ability of these cells to phagocytose either bacteria or Aβ
ﬁbrils. Since the chronic stimulation of MG with either SA or Aβ results
in the formation of very large SGs to which SYK is recruited, we propose
that it is the sequestration of the kinase away fromphagocytic receptors
that underlies the impaired phagocytic activity of MG. An enhanced ac-
cumulation of Aβ plaques in the brain would be an expected result of
exposure to oxidative stress due to this loss of phagocytic activity of
stressed MG. The exposure of MG to Aβ or Aβ ﬁbrils alone also induces
the appearance of abundant SGs, consistent with the known ability of
Aβ to trigger MG cell activation and promote the generation of ROS
and RNS (Bianca et al., 1999; Combs et al., 2001). Thus, a defect in the
removal of Aβ ﬁbrils by MG compromised by oxidative stress could
cause a build-up of Aβ plaques leading to additional Aβ-induced stress
and the enhanced formation of persistent SGs. In a mouse model of
AD, the phagocytic activity of MG is selectively compromised in brain
regions containing Aβ plaques (Krabbe et al., 2013). This would be par-
ticularly problematic in aged brains as our evidence indicates that MG
from older mice are more sensitive to Aβ-induced formation of SGs.
The critical role that SYK plays in modulating immune cell signaling
pathways has generated considerable interest in the development of in-
hibitors of SYK for the treatment of inﬂammatory diseases (Geahlen,
2014) including, recently, Alzheimer's disease (Paris et al., 2014).
While SYK inhibitors might reasonably be expected to reduce the acti-
vation of MG and production of inﬂammatory mediators, inhibitors
also block phagocytosis. This may complicate the development of strat-
egies for the use of speciﬁc SYK inhibitors for the treatment or preven-
tion of AD. However, the ﬁnding that active SYK is sequestered in SGs
suggests that strategies to relocate the enzymemight be effective in re-
storing some function to damaged MG. We ﬁnd that the treatment of
chronically stressed MG with rabbit IgG leads to a dramatic restoration
of phagocytic activity. The recovery of activity is not a function of the
reactivity of the IgG to any speciﬁc antigen as even an afﬁnity-puriﬁed
antibody prepared against a peptide found on the cytoplasmic domain
of an ITIM-containing receptor is able to induce this effect. Treatment
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plasmamembrane in unstressed cells and from SGs to themembrane in
chronically stressed cells. This effect may help explain the therapeutic
beneﬁts of intravenous immunoglobulins (IVIg), which have shown ef-
ﬁcacy in slowing the progression of AD in some human clinical trials
(Dodel et al., 2002; Dodel et al., 2004; Relkin et al., 2009; Loefﬂer,
2013). The beneﬁts of IVIg are generally attributed to the presence of
anti-Aβ antibodies in the pooled IgG preparations (Dodel et al., 2004).
However, it is interesting to note that the administration of pooled
mouse IgG having no detectable anti-Aβ activity to the brains of APP/
PS1 mice leads to a reduction in Aβ deposits similar to IVIg (Sudduth
et al., 2013). Thus, even immunoglobulins that fail to recognize Aβ
have the potential to reverse defects in the function of stressed MG.
This observation suggests that the development of IgG-related thera-
peutics optimized for the recovery of phagocytic activity of MG would
be an attractive strategy for augmenting current strategies for the
treatment of AD.
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.ebiom.2015.09.053.
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